Novel Food and Seaweed in the EU: What the 2025 Rules Mean

Your mozuku may have been sold legally in Europe for 10 years. That does not mean it is authorized. It means no one has challenged it yet.

That distinction matters more than most seaweed brands will ever tell you. The EU Novel Food framework is not a passive system that tolerates grey-area products indefinitely. It is an authorization-first regime: if a food was not consumed to a significant degree in the EU before 15 May 1997, selling it requires pre-market clearance. Full stop.

This article walks through what Regulation (EU) 2015/2283 actually says, which authorization pathway applies to which product, where Cladosiphon okamuranus (Okinawa mozuku) stands in 2025, and what a genuinely compliant seaweed product looks like under current EU law.

---

What "Novel Food" Actually Means for Seaweed Under EU Law

Under Article 3(2)(a) of Regulation (EU) 2015/2283, a food is "novel" if it was not consumed to a significant degree within the Union before 15 May 1997. That single date governs most of the seaweed market in Europe.

The regulation did not create a list of prohibited foods. It created a pre-authorization requirement for foods that lacked a documented European consumption history at the cutoff date. The burden of proof sits entirely with the operator who wants to sell the product, not with the authority that wants to stop it.

The 1997 Cutoff and Why Asian Seaweeds Almost Always Fail It

European consumption of seaweed before 1997 was largely limited to a handful of species: certain Porphyra (nori used in processing), Fucus vesiculosus for supplements, Undaria pinnatifida in some coastal markets. The broad category of Japanese brown algae, including mozuku, wakame used as a whole food, and kombu, had no documented significant consumption in EU member states before that date.

"Significant degree" is interpreted strictly. A product served in a handful of Japanese restaurants in Paris or Amsterdam in the 1990s does not constitute significant EU consumption. Documented traditional use in Japan counts for nothing under the standard Article 10-13 pathway. It becomes relevant only under a separate mechanism, Article 14, discussed below.

The practical consequence: virtually every Japanese seaweed species, consumed for centuries in Okinawa or on the Sanriku coast, enters the EU legal system as a Novel Food requiring authorization before it can be placed on the market.

Whole Seaweed vs. Seaweed Extract: Two Completely Different Legal Regimes

This is the most misunderstood distinction in the seaweed supplement market, and it has direct consequences for what you can legally buy.

A whole dried seaweed (the leaf, thallus, or powder thereof) and a concentrated extract from that same seaweed are treated as distinct foods under EU Novel Food law. Authorization for one does not carry over to the other.

The practical implication: if a fucoidan extract from Undaria pinnatifida (wakame) is authorized under Regulation (UE) 2017/2470, that authorization applies specifically to that extract at those concentrations. It does not authorize the whole algae as a food ingredient. It does not authorize a different fucoidan source, such as mozuku. And it does not authorize a mozuku whole-leaf powder simply because mozuku also contains fucoidan.

Two products can share an active compound, share a genus, share a harvest origin, and still face entirely different legal requirements. Operators and consumers who conflate them are navigating by the wrong map.

---

The Two Authorization Pathways: Why One Takes 4 Years and the Other Might Take 4 Months

Regulation (EU) 2015/2283 offers two routes to legal market access for novel foods.

The standard pathway, under Articles 10 to 13, involves submitting a dossier to EFSA. The agency has 9 months to issue a scientific opinion; the Commission then has 7 months to act on it. Those are the statutory deadlines. In practice, given requests for supplementary data and administrative steps, the process typically runs 2 to 4 years. It is expensive, technically demanding, and requires significant scientific evidence on safety, composition, and proposed conditions of use.

The second pathway, under Article 14, applies to traditional foods from third countries. This is where it gets interesting for Japanese seaweed.

Article 14 and Japanese Seaweed: A Pathway No One Has Used Yet

Article 14 was designed for foods with a history of safe use outside the EU. If a food has been part of a traditional diet in a non-EU country for at least 25 years (covering a significant part of the population of that country), an operator can notify the Commission and request access under a simplified procedure.

Under Article 15(2), EU member states and EFSA have four months to submit duly reasoned safety objections after a valid notification has been forwarded by the Commission. Where no such objections are raised, the Commission authorises the placing on the market and updates the Union list. The key nuance is that the four months are the objection window, not the entire real-world calendar from first filing to authorisation.

Mozuku has been consumed in Okinawa for well over 25 years at a scale exceeding 20,000 tonnes per year. It is, on paper, a plausible candidate for the Article 14 pathway for the whole algae as a food.

That is a striking gap. The Article 14 route is underused in the seaweed category, and entirely unused for Japanese species. Whether that reflects a lack of awareness, the cost of preparing documentation, or strategic calculation by potential applicants is unclear. What is clear is that the pathway exists, and no one has walked down it yet for mozuku or any other Japanese algae.

---

Where Mozuku (Cladosiphon okamuranus) Actually Stands in 2025

As of 2025, Cladosiphon okamuranus as a whole food is not listed in the EU Novel Food catalogue. It has no standalone authorization under Regulation (UE) 2017/2470. It has not been the subject of a successful Article 14 notification.

That means any product containing whole mozuku, sold as a food or food supplement in the EU, is operating without formal authorization under the Novel Food framework, unless an operator has obtained a country-level clearance through a national competent authority (an impermanent and non-harmonized status).

The Commission's Novel Food catalogue is explicitly non-binding. Member states can diverge in how they apply it. A product tolerated in one EU country may face enforcement action in another.

The Fucoidan Precedent from Wakame: What It Does and Doesn't Prove

Regulation (UE) 2017/2470 authorizes two fucoidan extracts: fucoidan from Fucus vesiculosus at 250 mg per day, and fucoidan from Undaria pinnatifida (wakame) at 250 mg per day, in both supplements and foods.

In April 2024, EFSA published a safety opinion on fucoidan extracted from Cladosiphon okamuranus (DOI: 10.2903/j.efsa.2024.8879). The dossier was submitted in 2020 by H. Holstein GmbH. EFSA concluded that the extract is safe at the proposed conditions of use.

The EFSA opinion is a necessary step, not a sufficient one. Until the Commission adopts the implementing regulation and adds mozuku fucoidan to the authorized list in Regulation (UE) 2017/2470, the extract remains unauthorized for commercial use in the EU. The science is ahead of the law, which is not unusual in this framework.

For a deeper look at what fucoidan is and what the evidence says about its biological activity, see Fucoidan: the complete guide to what it is and what it does.

---

The Regulatory Blind Spot: Iodine Has No Harmonized EU Ceiling for Seaweed

Regulation (EU) 2023/915 sets maximum levels for cadmium and lead in seaweed supplements: 3.0 mg/kg for both, applicable to supplements containing 80% or more dried algae. These are clear, harmonized limits.

Iodine is a different story. Despite being one of the primary safety concerns with high-seaweed diets (some brown algae species contain iodine at levels that can disrupt thyroid function with regular consumption), the EU has no harmonized maximum level for iodine in seaweed-based foods or supplements.

Member states handle this inconsistently. Germany and some Nordic countries apply national guidance values. France has issued warnings about high-iodine seaweed products. But there is no EU-wide ceiling, no mandatory labeling threshold, and no standardized testing requirement across the single market.

Key fact: The EU has harmonized cadmium and lead limits for seaweed supplements (3.0 mg/kg each under Regulation (EU) 2023/915), but has no harmonized maximum level for iodine in algae-based products. This is a documented gap in the current framework.

For consumers relying on EU compliance as a proxy for safety, iodine is the variable that compliance paperwork will not necessarily catch.

---

What "Compliant" Actually Looks Like: The Verification Checklist

Regulatory compliance for a seaweed supplement in the EU is not a single certificate. It is a stack of overlapping requirements. Here is what each layer looks like when it is genuinely in place.

Novel Food status: The operator should be able to point to a specific entry in Regulation (UE) 2017/2470, a positive Article 14 notification outcome, or a documented national authorization. "We've been selling this for years without any issues" is not a legal status.

Heavy metal testing: Third-party lab reports, ideally from ISO 17025-accredited laboratories, showing cadmium and lead results at or below 3.0 mg/kg. Results should be batch-specific, not a single historical test applied to all production.

Iodine content disclosure: Given the absence of harmonized EU limits, responsible operators measure iodine content and disclose it on labeling, enabling consumers to make informed decisions about total iodine intake. This is not legally required; it is a differentiator between operators who take safety seriously and those who do not.

Origin and harvest traceability: For Okinawa mozuku specifically, a product that cannot trace its harvest to a specific prefecture and season is a product with no meaningful quality anchor. Third-party certification (organic, aquaculture standards) provides additional verification.

For a broader look at what the EU regulatory framework requires from seaweed supplement operators, the pillar guide Buying Seaweed Supplements Safely in Europe: The Regulatory Truth covers the full picture.

---

What the Science and Law Actually Say

Three levels of evidence apply to any seaweed product making health-related claims in the EU.

Level 1: Authorized Novel Food status. The product has passed EFSA scientific review and received a Commission implementing regulation. The fucoidan extracts from Fucus vesiculosus and Undaria pinnatifida are at this level, at 250 mg/day under Regulation (UE) 2017/2470. Mozuku fucoidan extract is not yet at this level, despite a positive EFSA opinion.

Level 2: EFSA scientific opinion without implementing regulation. The science has been reviewed and found acceptable, but the legal authorization has not been issued. Mozuku fucoidan extract (EFSA 2024, DOI: 10.2903/j.efsa.2024.8879) sits here. The evidence is credible; the legal status is pending.

Level 3: Research without regulatory review. Animal studies, in vitro data, and traditional use documentation. Valuable for understanding mechanisms; insufficient for authorization claims. Most of the published fucoidan literature sits in this category.

Any brand claiming EU authorization for a mozuku product without a specific reference to Regulation (UE) 2017/2470 or a documented Article 14 clearance is either misinformed or misleading. Those are the only two possibilities.

For context on what mozuku is and how it is traditionally consumed in Okinawa, see What Is Mozuku Seaweed? The Complete Guide.

---

Frequently Asked Questions

Is mozuku legal to sell in Europe? Selling whole mozuku as a food in the EU requires Novel Food authorization under Regulation (EU) 2015/2283, which mozuku does not currently have. Some operators sell it under national tolerances or legal grey areas. That is not the same as authorization.

Is mozuku fucoidan extract authorized in the EU? Not yet. EFSA published a positive safety opinion in April 2024 (DOI: 10.2903/j.efsa.2024.8879), but a Commission implementing regulation is still required. Until that regulation is published, mozuku fucoidan extract is not on the EU authorized list.

What fucoidan sources are legally authorized in the EU? Under Regulation (UE) 2017/2470: fucoidan from Fucus vesiculosus and fucoidan from Undaria pinnatifida (wakame), both at a maximum of 250 mg/day in supplements and foods.

Does Japanese traditional use count toward EU Novel Food authorization? Not under the standard Article 10-13 pathway. Under Article 14 (traditional food from third countries), documented traditional use in Japan could support an expedited notification. No Japanese seaweed operator has filed an Article 14 notification to date.

What should I look for on a seaweed supplement label to assess compliance? Look for: a specific Novel Food authorization reference, batch-level heavy metal test results from an accredited laboratory, iodine content disclosed per serving, and traceable origin. If none of these are present, ask the operator directly before purchasing.

---

Summary

• Under Article 3(2)(a) of Regulation (EU) 2015/2283, any food without significant EU consumption before 15 May 1997 requires pre-market Novel Food authorization. Most Japanese seaweeds, including mozuku, fall into this category.
• Whole seaweed and seaweed extract are distinct legal objects. Authorization for one does not transfer to the other.
• The Article 14 traditional food pathway has a four-month objection window after validity review, but the full real-world calendar is longer and still requires a Commission implementing act. No Japanese seaweed operator has used it yet.
• Cladosiphon okamuranus whole algae has no EU Novel Food authorization. Mozuku fucoidan extract has a positive EFSA opinion (2024) but awaits the Commission implementing regulation.
• Fucoidan from Fucus vesiculosus and Undaria pinnatifida is authorized at 250 mg/day under Regulation (UE) 2017/2470.
• The EU has harmonized cadmium and lead limits for seaweed supplements (3.0 mg/kg, Regulation (EU) 2023/915) but no harmonized iodine ceiling, a documented gap.
• "Sold in Europe for years" is not an authorization. It is an absence of enforcement.

---

This content is for informational purposes only. It does not constitute legal advice. For questions about the regulatory status of your specific product, consult a food law specialist or contact the competent authority in your country.